Pancreatic Cancer Research

ResearcherUniversity of KentuckyActive in the last 2 years

Aditi Jain

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9383-7501; OpenAlex author ID A5061350811; NIH RePORTER profile ID 78231695. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 1)
Trials
0
Grants
1
Labs led
1
Collaborators
41
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 3 papers · 2020: none · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper, 1 grant · 2025: 6 papers

Papers 17

  1. Clinical Implications of Mismatch Repair Deficiency in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.70960↗
  2. P53 Function Status Correlates With Overall Survival in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1002/jso.70060↗
  3. Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.neo.2025.101152↗
  4. Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002458↗
  5. Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Cells in Hypercapnia Identifies SIAH3 as a Novel Prognostic Biomarker. Co-author DOI 10.3390/ijms26072848↗
  6. BARD1: A Friend or Foe in Pancreatic Ductal Adenocarcinoma? First author DOI 10.3390/ijms26189041↗
  7. The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm13072103↗
  8. Deletion of the mRNA stability factor ELAVL1 (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity. Co-author DOI 10.1093/narcan/zcad016↗
  9. The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1128/mcb.00018-22↗
  10. HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms. Co-author DOI 10.3390/cancers14071848↗
  11. The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Co-author DOI 10.1158/1535-7163.mct-20-0652↗
  12. AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition. First author DOI 10.1158/1541-7786.mcr-20-0985↗
  13. Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. Co-author DOI 10.3748/wjg.v27.i39.6527↗
  14. Evaluation of Post-transcriptional Gene Regulation in Pancreatic Cancer Cells: Studying RNA Binding Proteins and Their mRNA Targets. Co-author DOI 10.1007/978-1-4939-8879-2_22↗
  15. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-3645↗
  16. Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. Co-author DOI 10.1158/1541-7786.mcr-19-0589↗
  17. Biochanin A reduces pancreatic cancer survival and progression. Co-author DOI 10.1097/cad.0000000000000044↗

Grants 1

  1. Elucidating the relevance of BARD1-PLK1 interaction in PDAC and response to therapy R03CA283232↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Charles J. Yeo · 12 shared papers, 2019–2025 · strength 2.15
  2. Avinoam Nevler · 10 shared papers, 2019–2025 · strength 1.91
  3. Harish Lavu · 5 shared papers, 2024–2025 · strength 1.27
  4. Jonathan Robert Brody · 9 shared papers, 2019–2025 · strength 1.17
  5. Wei Jiang · 5 shared papers, 2019–2025 · strength 0.91
  6. Rosalie C. Sears · 4 shared papers, 2022–2025 · strength 0.68
  7. Matthew McCoy · 4 shared papers, 2021–2025 · strength 0.60
  8. Samantha Z. Brown · 5 shared papers, 2019–2022 · strength 0.58
  9. Lily Zekavat · 1 shared paper, 2025 · strength 0.54
  10. Faria Nusrat · 2 shared papers, 2024–2025 · strength 0.47
  11. Michael Jon Pishvaian · 4 shared papers, 2019–2025 · strength 0.47
  12. Grace A. McCarthy · 4 shared papers, 2019–2023 · strength 0.45
  13. Talia Golan · 4 shared papers, 2019–2021 · strength 0.37
  14. Christopher William Schultz · 4 shared papers, 2019–2022 · strength 0.37
  15. Vikas Bhardwaj · 2 shared papers, 2014–2021 · strength 0.33
  16. Zachary Kaplan · 1 shared paper, 2025 · strength 0.28
  17. Hui Chen · 1 shared paper, 2025 · strength 0.26
  18. Nitzan Zohar · 1 shared paper, 2025 · strength 0.26
  19. Richard Zheng · 1 shared paper, 2025 · strength 0.26
  20. Sohum D. Patel · 1 shared paper, 2025 · strength 0.23
  21. Dan A. Dixon · 2 shared papers, 2021–2022 · strength 0.22
  22. Alex O. Haber · 2 shared papers, 2019–2021 · strength 0.21
  23. Alexander Savio Ramos Guimaraes · 1 shared paper, 2023 · strength 0.17
  24. Jennifer M. Finan · 1 shared paper, 2023 · strength 0.17
  25. Yifei Guo · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.